Clinical trial
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated…
NCT00475150 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00475150 |
|---|---|
| Title | Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome |
| Official title | A Phase II Study of AZD2171 in the Treatment of Patients With Acute Leukemia and Myelodysplastic Syndrome. |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13, q22), Adult Acute Myeloid Leukemia With t(15, 17)(q22, q12), Adult Acute Myeloid Leukemia With t(16, 16)(p13, Adult Acute Myeloid Leukemia With t(8, 21)(q22 and 6 more |
| Intervention type | Drug, Other |
| Interventions | cediranib maleate, laboratory biomarker analysis |
| Enrollment | 39 |
| Start date | May 1, 2008 |
| Primary completion | Jul 1, 2011 |
| Completion | Mar 1, 2012 |
| First posted | May 17, 2007 |
| Last update posted | Feb 15, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: